Festal, ind. 10 pcs.

Pharmacological group: digestive enzyme agent.

ATX code: A09AA02

Pharmacological action

The drug compensates insufficiency of external pancreatic secretory function due to pancreatin, and biliary function of the liver due to the bile component. Festal has proteolytic, amylolytic and lipolytic action. As part of pancreatin enzymes: amylase, lipase and protease facilitate the digestion of carbohydrates, fats and proteins, which contributes to their more complete absorption in the small intestine. And in this respect Festal is practically no different from other enzyme preparations.

The presence in Festal of bile acids gives the drug additional possibilities for the correction of biliary insufficiency, which often accompanies chronic pancreatitis. Bile extract has a choleretic effect, facilitates absorption of fats and fat-soluble vitamins A, E, and K, and promotes secretion of lipase by the pancreas.

Indications

Lack of external pancreatic secretory function in chronic pancreatitis combined with biliary insufficiency due to various pathological conditions, clinically manifested by impaired digestion, flatulence, tendency to constipation, as a part of combined therapy in

– diffuse liver disease – alcoholic and toxic liver damage, cirrhosis;

– large losses of bile acids (in patients after cholecystectomy);

– impaired bile acid circulation, seen in biliary dyskinesia, dysbacteriosis, malabsorption;

– impairment of neurohumoral regulation of the processes of bile formation and bile discharge in chronic diseases of the gastrointestinal tract – chronic gastritis, chronic duodenitis, chronic cholecystitis;

For improving digestion in patients with normal function of the gastrointestinal tract in case of poor diet as well as in cases of impaired mastication, forced prolonged immobilization, sedentary lifestyle.

Preparing for radiological and ultrasonic examination of the abdominal cavity.

Active ingredient

Composition

How to take, the dosage

Interaction

Simultaneous use with the drug Festal® increases absorption of PASC (p-aminosalicylic acid), sulfonamides, antibiotics.

Long-term use of pancreatin may decrease absorption of iron preparations.

The concomitant use of antacids containing calcium carbonate and/or magnesium hydroxide may decrease the effect of pancreatin.

Cimetidine may increase the effect of pancreatin.

Pancreatin may decrease the effect of acarbose, therefore the drug Festal® and acarbose should not be used simultaneously.

Pancreatin may decrease absorption of folic acid.

Special Instructions

Synopsis

Contraindications

Side effects

According to the World Health Organization (WHO), adverse reactions are categorized into system-organ classes with the frequency of occurrence as follows: Very common (≥1/10), common (≥1/100,

< 1/10), infrequent (≥1/1000, < 1/100), rare (≥1/10000, < 1/1000) and very rare (< 1/10000); frequency unknown (frequency of events cannot be determined from available data).

Immune system disorders: frequency unknown – anaphylactic reactions, including urticaria and angioedema.

Renal and urinary tract disorders: frequency unknown – there are reports of cases of hyperuricosuria with prolonged use of high doses of pancreatin.

Gastrointestinal disorders: frequency is unknown – abdominal pain, diarrhea, vomiting, irritation of the mucous membrane of the mouth (see

“Special indications”), anal itching. In patients with cystic fibrosis when taking high doses of pancreatin (significantly higher than those recommended for the drug Festal®) in some cases the development of constipation, colonic stenosis, intestinal obstruction, fibrosing colonopathy,

Mechanism and nutrition disorders: frequency unknown – hyperuricemia (in overdose of pancreatin).

Overdose

The symptoms of overdose are hyperuricemia and hyperuricosuria. If symptoms of overdose occur, the drug should be discontinued and symptomatic therapy should be carried out.

In case of overdose, the drug should be discontinued and symptomatic therapy should be carried out.

Pregnancy use

Similarities